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Coinfection with hepatitis C virus (HCV) and
HIV is an emerging public health problem. While
coinfection with HIV can accelerate the progres-
sion of HCV (1,2), the impact of dual infection on
other infectious diseases is unknown. We
describe the first reported case of meningococcal
infection in a patient coinfected with HCV and
HIV.
Case Report
A 45-year-old woman was admitted to our
hospital emergency department in September
1999 with influenza-like symptoms (36 hours)
and fever, headache, and myalgias (12 hours).
The patient’s medical history included ongoing
injection drug use, coinfection with HIV and
HCV, an episode of Staphylocccus aureus cervical
osteomyelitis, three culture-confirmed episodes
of  Streptococcus pneumoniae pneumonia, and
HIV-associated thrombocytopenia. Her most
recent CD4 count was 149 cells/µL, and in April
1999, her plasma HIV RNA level was 2,000 viral
copies/ µL. She had received pneumococcal
polysaccharide vaccine in 1996. Because of
ongoing injection drug use, she had never
received antiretroviral therapy. Her medications
included trimethoprim/sulfamethoxazole, parox-
etine, nifedipine, furosemide, and methadone.
The patient was lethargic (oral temperature
40.3°C, blood pressure 82/45 mm Hg, pulse rate
100 beats per minute, and respiratory rate 24
breaths per minute). Physical examination
showed meningismus, bilateral conjunctival
hemorrhages, diffuse petechiae, and tender
palpable purpura on the lower extremities.
Neurologic examination was nonfocal. Initial
laboratory findings were as follows: hematocrit,
46%; platelet count, 69 x 109/L; leukocyte count,
6.0 x 109/L; creatinine, 1.6 mg/dL; aspartate
aminotransferase, 61 U/L; alanine aminotrans-
ferase, 28 U/L; total bilirubin, 0.8 mg/L; alkaline
phosphatase, 96 U/L; prothrombin time/interna-
tional normalized ratio,14.1 seconds/1.3; partial
thromboplastin time, 29.4 seconds. Urinalysis
showed 14 red blood cells and 28 leukocytes per
high-power field, no casts, and 3+ proteinuria. A
later urinalysis showed that both the proteinuria
and cellular elements had resolved. No schisto-
cytes were visible on peripheral blood smear. A
skin lesion biopsy performed in the emergency
room revealed a thrombotic vasculopathy
without evidence of rickettsiae (by direct
immunoflourescence) or other microorganisms.
Because of concern for possible bacterial
meningitis, the patient was immediately given 2
g ceftriaxone intravenously. After computed
tomography of the brain revealed no acute
intracranial process, lumbar puncture was
performed. The cerebrospinal fluid was cloudy,
with 7,675 nucleated cells/mm (92% neutrophils
and 3% band forms). Protein was 382 mg/dL, and
glucose was less than 20 mg/dL. Gram stain
showed 3+ gram-negative diplococci. Cultures of
the cerebrospinal fluid and blood yielded pure
growth of serogroup Y Neisseria meningitidis.
The patient received a 10-day course of
intravenous ceftriaxone, 2 g every 12 hrs. Whole
hemolytic complement (CH50) drawn on hospital
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day 5 was 13 units (23-52 units). Other
complement assays included a C3 value of 105
mg/dL (86-208 mg/dL) and a C4 value of 8 mg/dL
(13-47 mg/dL. Results of a cryoglobulin screen
were positive. Computed tomography of the
abdomen revealed nodular liver and splenomega-
ly consistent with cirrhosis. The patient was
given meningococcal vaccine near the end of her
hospital course and was discharged with no
sequelae. On follow-up with her primary
physician, she had no evidence of complications
from the meningococcemia. A repeat CH50
drawn 6 months after hospitalization was <10
units (23-52 units).
Conclusions
To our knowledge this is the first reported
case of disseminated meningococcemia in a
patient coinfected with HIV and HCV. Because
coinfected patients constitute an increasing
percentage of patients infected with HIV (2),
several features of this case bear emphasis.
First, hepatic dysfunction from conditions
such as HCV is an important risk factor for
meningococcal disease (3). This increased risk is
likely due to decreased hepatic synthesis of
complement (3). Because hypocomplementemia
occurs commonly in patients infected with HCV,
particularly when cirrhosis or cryoglobulinemia
is present (4), these patients are at increased risk
for meningococcal infection (3). Patients who are
coinfected with HIV and HCV may be at even
greater risk for meningococcal infection because
of accelerated hepatic destruction. For example,
patients coinfected with HIV and HCV have a
higher progression to hepatic fibrosis (1) and a
3.5-fold increase in hepatic cirrhosis (2), when
compared to patients with HCV alone. Given that
up to 9% of HIV-infected patients may be
coinfected with HCV (2), a group of patients with
potentially increased susceptibility to meningo-
coccal infection may be emerging.
Second, unlike the interaction between HIV
and  S. pneumoniae,  Salmonella, and other
recognized bacterial opportunistic pathogens,
the interaction between HIV and meningococcus
is unclear. Fewer than 50 cases of meningococcal
infections in HIV-infected patients have been
reported in  MEDLINE (5-14). These reports
present conflicting results on the impact of HIV
infection on the risk for meningococcal disease.
For example, while one recent prospective cohort
study reported an increased risk for meningococcal
disease (relative risk 23.8, confidence interval
7.4-76.7; p <0.001) in HIV-infected patients in
the Atlanta metropolitan area (12), a case-control
study in Africa showed no link between HIV
infection and epidemic meningococcal disease
(14). Despite the low rate of reported infection,
asymptomatic colonization with meningococcus
occurs in as many as 15%-23% of tested cohorts of
both HIV-infected patients (15) and healthy
young adults (16).
There are limitations to our report. Because
our patient had several pneumococcal infections
before the meningococcemia, immunologic de-
fects other than hypocomplementemia (such as
advanced HIV) may have contributed to
susceptibility to both of these bacterial patho-
gens. Only limited data may be inferred from a
single case. For example, assuming that the
overall rate of meningococcal disease in the
United States is 1/100,000, that 1% of the U.S.
population is HIV positive, and that 9% of these
patients are coinfected with HCV, only two to
three cases of meningococcal infection would be
expected to occur among coinfected patients if no
additional risk for meningococcal infection were
present. Because the true incidence of meningo-
coccal infection among coinfected patients is
unknown, future cohort studies will have to
establish the impact of coinfection with HIV and
HCV on the risk for meningococcal infection.
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